Enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) demonstrated a statistically significant improvement in overall survival (OS) compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results of the final OS analysis of the phase III PROSPER trial.1
Enzalutamide was initially approved in 2012 as a treatment for men with metastatic CRPC following prior docetaxel therapy, and it was later expanded to be used prior to chemotherapy.
- Xtandi (enzalutamide) demonstrates significant improvement in overall survival in phase 3 prosper trial of patients with NMCRPC [news release]: Tokyo, Japan and New York NY. Astellas Pharma, Inc., and Pfizer. Published February 11, 2020. Accessed February 12, 2020.
- Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Eng J Med. 2018;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
- Hussain M, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2018;36(suppl 6S; abstr 3).
- Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2.
... to read the full story